Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.ZEBOV + MVA-BN-Filo (Janssen Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EBL2007 refers to a clinical trial (NCT04186000) evaluating the heterologous two-dose Ebola vaccine regimen consisting of Ad26.ZEBOV (Zabdeno) and MVA-BN-Filo (Mvabea). Developed by Janssen (Johnson & Johnson) and Bavarian Nordic, this prophylactic vaccine regimen is designed to prevent Ebola virus disease caused by the Zaire ebolavirus species. The regimen involves a prime dose of Ad26.ZEBOV, a recombinant, replication-incompetent adenovirus type 26 vector expressing the Zaire ebolavirus Mayinga glycoprotein, followed approximately 56 days later by a booster dose of MVA-BN-Filo, a recombinant, non-replicating modified vaccinia Ankara vector expressing glycoproteins from Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, as well as the nucleoprotein from Taï Forest ebolavirus. The regimen received marketing authorization in the European Union in July 2020 and WHO prequalification in May 2021, though the EU marketing authorization was withdrawn in May 2026 for commercial reasons.
- Brand names
- MvabeaZabdenoZabdeno + MvabeaZabdeno/Mvabea
- Other names
- Ad26.ZEBOV + MVA-BN-FiloAd26.ZEBOV/MVA-BN-FiloEBL2007EBL-2007EBL 2007EBL2007 vaccine regimenEBL-2007 vaccine regimenEBL 2007 vaccine regimenJanssen Ebola vaccine regimen
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Ad26.ZEBOV + MVA-BN-Filo (Janssen Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.ZEBOV + MVA-BN-Filo (Janssen Pharmaceutical).